1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Interpharm Holdings, Inc.

Interpharm Holdings, Inc.

IPAH
Interpharm Holdings, Inc.US flagOther OTC
0.00
USD
- -
- -
270,768.00Market Cap
1995 Y
1996 Y
1997 Y
1998 Y
1999 Y
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
TTM
Revenue per Share
16.14
19.97
16.91
30.79
15.6
10.02
7.48
5.59
- -
2.34
1.55
1.73
1.16
1.05
Basic EPS, GAAP
-1.25
0.2
0.29
0.44
-0.62
0.04
-0.64
-0.24
- -
0.16
-0.01
-0.15
-0.26
-0.51
Free Cash Flow per Basic Share
-0.16
-0.2
0.49
-0.26
-0.15
-0.23
0.2
-0.01
- -
-0.13
-0.41
-0.17
-0.34
-0.45
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.01
- -
- -
Book Value per Share
-0.98
-0.1
0.2
0.66
-0.04
0.01
-0.63
-0.88
- -
0.23
0.14
-0.04
-0.28
-0.59
Tangible Book Value per Share
-1.2
-1.76
0.64
1.41
1.4
1.34
0.69
0.48
- -
1.28
0.9
0.62
0.17
-0.08
Basic Weighted Avg Shares
2
4
6
6
7
7
7
7
- -
18
26
37
65
66
Sales/Revenue/Turnover
30
82
101
187
107
72
53
39
- -
41
40
63
76
69
Operating Margin (%)
-1.68
1.71
2.58
2.56
-1.86
0.47
-8.58
-3.73
- -
12.31
-0.24
-7.52
-14.21
-28.49
Depreciation Expense
- -
- -
- -
- -
1
- -
- -
- -
- -
1
1
2
3
3
Net Income, GAAP
-2
1
2
3
-4
- -
-5
-2
- -
3
- -
-4
-14
-29
Effective Tax Rate (%)
- -
33.33
43.33
43.75
- -
25.48
- -
- -
- -
38.87
- -
- -
- -
- -
Profit Margin (%)
-7.74
0.98
1.69
1.44
-4
0.41
-8.53
-4.29
- -
7.6
-0.37
-5.98
-18.6
-42.42
Working Capital
1
4
4
8
9
9
5
4
6
12
2
9
2
-17
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
7
7
14
14
8
Total Equity
3
7
8
13
11
11
7
5
12
23
23
23
11
-5
Return on Invested Capital (%)
- -
12.44
14.81
17.65
- -
1.88
- -
- -
- -
13.57
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
103.85
- -
- -
- -
- -
- -
113.37
-8.17
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'07
Sep'08
Dec'08
ST Debt
12
18
31
LT Borrowings
14
14
8
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
66
67
Market Capitalization
1
1
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'07
Sep'08
Dec'08
Total Current Assets
32
32
27
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
13
16
14
Inventories
17
13
12
Total Current Liabilities
31
38
44
Payables & Accruals
19
11
7
ST Debt
12
18
31
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.81%
35.95%
-49.98%
Free Cash Flow
- -
- -
266.51%
Net Income, GAAP
- -
- -
270.92%
Sales/Revenue/Turnover
- -
- -
19.31%
Total Cash Common Dividend
- -
- -
76.86%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
15
16
16
16
63
2007
23
17
20
15
76
2008
18
16
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
-0.02
0.02
-0.05
- -
-0.15
2007
0.03
-0.07
-0.04
- -
-0.26
2008
-0.1
-0.21
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
0.01
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Raj Sutaria
Full Time Employees
670
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
75 Adams Avenue Hauppauge United States of America
IPO Date
Jan 3, 2000
Website
interpharmusa.com
Similar Companies
TMT (India) Ltd. (TMTIND-B1.BO)
Medi-Caps Limited (MEDICAPQ.BO)
Vikram Thermo (India) Limited (VIKRAMTH.BO)
Genky DrugStores Co., Ltd. (9267.T)
Norris Medicines Limited (NORRIS.BO)
Sastasundar Ventures Limited (SASTASUNDR.NS)
Business
Interpharm Holdings, Inc. engages primarily in the development, manufacture, and marketing of generic pharmaceutical products. Its core offerings encompass a comprehensive portfolio of generic drugs, including oral solids, injectables, and controlled substances, with notable capabilities in hormonal and high-potency drug production. The company operates through wholly owned subsidiaries and maintains manufacturing facilities in Long Island, New York. Founded in 1984 and headquartered in New York, Interpharm serves a diverse customer base that includes pharmacies, hospitals, clinics, and healthcare distributors in the United States. The latest major change for Interpharm Holdings is its acquisition by Amneal Pharmaceuticals in 2008, which integrated Interpharm's manufacturing facilities, intellectual property, and extensive product line into Amneal's operations. This strategic move expanded Amneal's manufacturing capabilities and broadened its generic product portfolio substantially, allowing for accelerated growth and increased market presence in the generic pharmaceuticals sector. Interpharm’s product lines include over one hundred approved or filed products regulated by the USFDA, spanning oral solids, liquids, injectables, and specialized formulations such as soft gelatin capsules and controlled substances. The acquisition has leveraged Amneal's financial strength and research and development capacity to enhance product development and commercialization efforts. Interpharm Holdings operates mainly in the pharmaceuticals industry within the broader pharmaceuticals and biotechnology sector, targeting primarily the generic drug market in the United States. Its business model includes extensive contract development and manufacturing offerings, supporting a broad range of complex generic pharmaceuticals. The company maintains a robust research pipeline and benefits from strong regulatory compliance. Interpharm’s strategic focus on vertical integration and manufacturing excellence underpins its competitive position and operational efficiencies within the generic pharmaceutical marketplace. The affiliation under Amneal Pharmaceuticals marks a significant operational and strategic evolution for the company in recent years.